Quick Answer
LEXICON PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $6.00 million for fiscal year 2024.
LEXICON PHARMACEUTICALS, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2024 | $6.00M | +440.6% |
| 2023 | $1.11M | — |
| 2022 | $0.00 | — |
| 2021 | $0.00 | -100.0% |
| 2020 | $23.40M | -27.6% |
| 2019 | $32.33M | +21.6% |
| 2018 | $26.58M | +67.3% |
| 2017 | $15.89M | — |
| 2016 | $0.00 | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| March 31, 2025 | $1.26M | +15.5% | -27.5% |
| September 30, 2024 | $1.74M | +1076.4% | +7.7% |
| June 30, 2024 | $1.62M | +455.7% | +47.9% |
| March 31, 2024 | $1.09M | — | +638.5% |
| September 30, 2023 | $148.0K | — | -49.1% |
| June 30, 2023 | $291.0K | — | — |
| March 31, 2023 | $0.00 | — | — |
| September 30, 2022 | $0.00 | — | — |
- LEXICON PHARMACEUTICALS, INC. showed an increase of +440.6% in Revenue (ASC 606) compared to the prior fiscal year.
- The most recent figure is from LEXICON PHARMACEUTICALS, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 7, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: